« Return to News | CROs/Service Providers | Study Conduct

Biologics to Manage Cancer Study for National Marrow Donor Program

Thursday, February 18, 2010 09:38 AM

Biologics, a cancer management company that offers clinical trial materials management as part of its services, has been selected by the National Marrow Donor Program (NMDP) to manage a phase III clinical trial.

Biologics’ Oncology Clinical Trial Services division will provide pharmacy management services for the nonprofit organization’s clinical trial of filgrastim (Neupogen)-simulated peripheral blood stem cells (PBSC) in hematopoietic cell transplants involving unrelated donors. PBSC, according to the NMDP, is used more often than marrow for adult patients in need of allogeneic and autologous transplants.

Biologics will manage inventory and coordinate the delivery of 200 shipments of Neupogen a month to 50 NMDP donor sites as part of the trial. This process is particularly time-sensitive because the drug must be shipped overnight in temperature-controlled packaging to successfully support the transplant schedule. Although Biologics has just recently become involved in this clinical trial, the trial has been ongoing since 1997.

 

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.